A shorter 2 week course of radiation for diffuse midline glioma
Original title: Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so it is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests giving radiation over 2 weeks instead of 6 weeks for people with diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Who this trial is for. This trial is for people with a diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. It tests a change in how radiation is given, from 6 weeks of radiation to 2 weeks.
Where it stands. This trial has not reported results. It is looking at how people do with the shorter course of radiation, and at their quality of life. The answer is not in yet.
What this means, and what it doesn't
What it could mean: A shorter radiation schedule could mean fewer weeks of treatment. We do not yet know how it compares to the longer schedule. Someone who fits could ask their care team about this trial.
What it doesn't mean: This does not mean the shorter course is proven. A trial is a test, not a treatment that is known to work. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure. Only the trial team can decide who can take part.
Source: ClinicalTrials.gov, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.